UNITED STATES

OMB APPROVAL

SECURITIES AND EXCHANGE
COMMISSION

OMB Number:
3235-0145

Washington, D.C. 20549

Expires: February 28, 2009

SCHEDULE 13D

Estimated average burden hours per response. . 14.5

Item 1.

Security and Issuer

This statement relates to shares of common stock, $0.001 par value per share (the “Common Stock”), of Pro Pharmaceuticals, a Nevada corporation (the “Company”).  The Company’s principal executive offices are located at 7 Wells Avenue, Newton, Massachusetts.

Item 2.

Identity and Background

(a)           Name:  James C. Czirr  (the “Reporting Person”)

(b)           Residence:  425 Janish Drive, Sandpoint, ID 83864

(c)           Occupation:  Chief Executive Officer, Minerva Biotechnologies Corp. (see Item 2(b) for address)

(d)           During the past five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)           During the past five years, the Reporting Person was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which the Reporting Person was or is subject to any judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

(f)            Citizenship:  United States

Item 3.

Source and Amount of Funds or Other Consideration

Shares acquired in 2001 in exchange for shares of capital stock of Pro-Pharmaceuticals, Inc., a Massachusetts corporation, pursuant to that certain Stock Exchange Agreement dated April 25, 2001, a copy of which was filed with the Securities and Exchange Commission as an exhibit to the Company’s Form 10-SB on June 13, 2001.

Item 4.

Purpose of Transaction

This statement amends the statement filed by James Czirr on October 24, 2006.

The Reporting Person is pleased that the Company has created an independent position of President to report directly to the board of Directors and handle joint venture, investor, and financial matters. The Reporting Person believes that Dr. Ted Zucconi, the new President and member of the Board of Directors, is a positive addition to the Company in line with the Reporting Person’s prior recommendations to the Board of Directors for such position. 

The Reporting Person remains seriously concerned about the Company and its financial position, given the lasting effects of the Company’s ill-fated 2006 convertible debt financing and intends to continue to monitor the Company and its performance.  The Reporting Person may change his position with respect to the shares of the Company’s stock that the Reporting Person owns based on his assessment of pertinent factors, including, without limitation, the Company’s business and prospects; general economic conditions; stock market and money market conditions; the attitude and actions of the management and Board of Directors of the Company; and other plans and requirements of the Reporting Person.

Depending upon his assessment of these factors from time to time, the Reporting Person may change his present intentions as stated above or dispose of some or all of the shares of the Company’s common stock held by him in the open market, in privately negotiated transactions, to third parties or otherwise, and may sell such shares to one or more purchasers.  Although the foregoing represents the range of activities presently contemplated by the Reporting Person with respect to the Company’s common stock, the possible activities of the Reporting Person are subject to change at any time. 

Except as set forth in this Item 4 and elsewhere in this Statement, the Reporting Person does not have any plans or proposals which relate to or would result in any of the actions specified in Schedule 13D, and the Reporting Person reserves the right to change its intentions with respect to any of the foregoing at any time without notice.

Item 5.

Interest in Securities of the Issuer

(a)    Aggregate number and percentage of the Common Stock owned by the Reporting Person: 4,588,468 shares (1); 11.36% (2).

(b)    Number of shares which Reporting Person has sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition:  4,588,468.

(c)    None.

(d)    Not applicable.

(e)    Not applicable.

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

None.

Item 7.

Material to Be Filed as Exhibits

None.

(1) Shares of Common Stock beneficially owned by minor children of Mr. Czirr, as to which Mr. Czirr disclaims beneficial ownership. 

(2) Based on 40,364,792 total shares outstanding as of June 30, 2007.

Date:  October 30, 2007

Date

/s/ James C. Czirr

Signature

James C. Czirr

Name/Title